查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984875

全球外泌體療法市場：依外泌體來源、治療方法、治療環境、治療應用案例、給藥方法、監管分類和地區劃分－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Exosome Therapy Market: By Exosome Source Type, Treatment Setting, Therapeutic Use Case, Administration Approach, Regulatory Classification, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 320 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

外泌體療法市場正在經歷重大轉型，從一個投機性的小眾領域發展成為一個快速成長且具有顯著經濟價值的產業。目前，該市場價值 581 億美元，預計未來幾年將實現顯著成長，到 2035 年將超過 3,096 億美元。這一顯著擴張意味著 2026 年至 2035 年期間的複合年增長率 (CAGR) 將達到 18.20%，凸顯了投資者信心的增強以及基於外泌體的療法日益普及。

推動該市場發展的關鍵因素之一是從傳統的基於活幹細胞的療法轉向 "無細胞" 外泌體產品。 這種轉變源自於人們希望解決幹細胞療法面臨的挑戰，特別是安全性和可擴展性方面的擔憂。外泌體是由細胞分泌的微小細胞外囊泡，是一種很有前景的替代方案，因為它們保留了乾細胞的許多治療效果，而沒有細胞本身固有的風險。

主要市場趨勢

該行業的特點是競爭激烈，公司類型多樣，包括成熟的生物製藥公司、專業的生物技術公司和研究工具供應商。這種組合造就了一個充滿活力的環境，創新和策略舉措對於成功至關重要。每種類型的公司都為市場帶來獨特的優勢，從先進的研究能力到專業的技術平台，共同構成了一個豐富多元的競爭格局。

推動該領域發展的關鍵公司包括 Coya Therapeutics、Evox Therapeutics、Curexsys、EV Therapeutics、SHIFTBIO、Capriccio Therapeutics 和 Aethlon Medical。 這些公司不僅在推動自身技術發展，也積極透過各種策略措施來鞏固其市場地位。

除了建立合作關係外，這些公司還在大力投資開發符合良好生產規範 (GMP) 標準的可擴展生產技術。 這項措施確保生產流程符合嚴格的監管要求，這是生物製藥安全穩定生產的關鍵要素。

主要成長驅動因素

全球癌症發生率的上升是推動基於外泌體的免疫療法和標靶藥物遞送系統需求的關鍵因素。隨著全球癌症發生率的持續上升，迫切需要開發更有效、更精準的療法，以改善患者預後並最大限度地減少副作用。基於外泌體的療法因其能夠調節免疫系統並將治療藥物高特異性地直接遞送至腫瘤細胞，而備受關注。

新興機會

外泌體療法市場最具獲利潛力的機會不僅存在於再生醫學領域，也存在於藥物遞送領域。再生醫學因其修復和癒合受損組織的能力而備受關注，而外泌體作為一種高效的藥物遞送載體，其潛力正在成為一個具有更大商業前景的創新領域。 全球生物製藥市場現有藥物遞送系統的局限性，主要依賴脂質奈米顆粒（LNP）和病毒載體，這為外泌體療法市場的發展提供了機會。儘管這些技術已取得顯著成功，但它們往往存在一些重大缺陷，例如毒性或誘發免疫反應。

優化障礙

由於產業缺乏標準化和品質控制，外泌體療法市場的成長面臨嚴峻挑戰。目前，外泌體的分離、表徵和生產尚無普遍接受的方案，促使這些療法的生產方法有顯著差異。缺乏標準化流程導致批次間差異顯著，通常超過20%，這意味著外泌體產品的組成和品質可能因批次而異。這種異質性會削弱治療效果的可靠性和可預測性，而這些對於贏得臨床醫生、患者和監管機構的信任至關重要。

目錄

第一章 摘要整理：全球外泌體療法市場

第二章 研究方法與架構

  • 研究目標
  • 產品概述
  • 市場區隔
  • 質性研究
    • 一手和二手資料
  • 量化研究
    • 一手和二手資料
  • 主要調查受訪者分佈：依地區劃分
  • 本研究的假設
  • 市場規模估算
  • 數據三角測量

第三章 全球外泌體療法市場概論

  • 產業價值鏈分析
    • 原料和生物材料供應商
    • 外泌體分離與生產技術供應商
    • 合約開發與生產組織 (CDMO)
    • 治療開發公司和生技公司
    • 醫療保健提供者和臨床機構
  • 行業展望
    • 臨床開發趨勢
    • 監理環境
    • 疾病負擔與治療潛力
  • PESTLE 分析
  • 波特五力分析
    • 供應商議價能力
    • 買方議價能力
    • 替代品威脅
    • 新進入者威脅
    • 競爭強度
  • 市場成長與展望
    • 市場收入估算與預測（2020-2035 年）
    • 價格趨勢分析

第四章 全球外泌體療法市場分析

  • 競爭格局概覽
    • 市場集中度
    • 公司佔有率分析（價值，%），2025 年
    • 競爭對手分析與基準分析

第五章 全球外泌體療法市場分析

  • 市場動態與趨勢
    • 成長驅動因素
    • 限制因素
    • 機遇
    • 主要趨勢
  • 市場規模及預測（2020-2035 年）
    • 依治療方法
    • 依治療環境
    • 依給藥方法
    • 依外泌體類型來源
    • 依監理分類
    • 治療用途
    • 依地區

第六章：北美市場分析

第七章：歐洲市場分析

第八章：亞太市場分析

第九章：中東和非洲市場分析

第十章：南美市場分析

第11章 企業簡介

  • Aethlon Medical Inc.
  • Capricor Therapeutics Inc.
  • Codiak BioSciences
  • EV Therapeutics
  • Evox Therapeutics Ltd.
  • Exosome Sciences Inc.
  • ReNeuron Group plc
  • System Biosciences LLC
  • Aruna Bio, Inc.
  • NurExone Biologic
  • Aegle Therapeutics
  • Other Prominent Players

第12章 附錄

簡介目錄
Product Code: AA01261686

The exosome therapy market is undergoing a significant transformation, evolving from a speculative and niche segment into a rapidly expanding industry with substantial economic value. Currently valued at USD 58.1 billion, the market is projected to experience impressive growth over the coming years, with forecasts estimating it will exceed USD 309.6 billion by 2035. This remarkable expansion reflects a compound annual growth rate (CAGR) of 18.20% during the period from 2026 to 2035, highlighting both increasing investor confidence and growing adoption of exosome-based therapies.

One of the key factors driving this market evolution is the shift from traditional live stem cell therapies toward "cell-free" exosome products. This transition is motivated by the desire to address some of the challenges associated with stem cell treatments, particularly concerns related to safety and scalability. Exosomes, which are small extracellular vesicles secreted by cells, offer a promising alternative because they carry many of the therapeutic benefits of stem cells without the risks linked to the cells themselves.

Noteworthy Market Developments

The industry is characterized by intense competition and a diverse array of players, including well-established biopharmaceutical companies, specialized biotechnology firms, and providers of research tools. This blend creates a dynamic landscape where innovation and strategic maneuvering are essential for success. Each type of company brings unique strengths to the market, from advanced research capabilities to specialized technology platforms, contributing to a rich and multifaceted competitive environment.

Among the key participants driving progress in this sector are companies such as Coya Therapeutics, Evox Therapeutics, Curexsys, EV Therapeutics, SHIFTBIO, Capricor Therapeutics, and Aethlon Medical. These organizations are not only advancing their proprietary technologies but also actively seeking to strengthen their market positions through various strategic initiatives.

In addition to forging alliances, these companies are heavily investing in the development of scalable production technologies that comply with Good Manufacturing Practice (GMP) standards. This focus ensures that their manufacturing processes meet stringent regulatory requirements, which is crucial for the safe and consistent production of biopharmaceutical products.

Core Growth Drivers

The increasing global incidence of cancer is a significant factor driving the demand for exosome-based immunotherapy and targeted drug delivery systems. As cancer rates continue to rise worldwide, there is an urgent need for more effective and precise treatment options that can improve patient outcomes while minimizing side effects. Exosome-based therapies have garnered considerable attention in this context because of their ability to modulate the immune system and deliver therapeutic agents directly to tumor cells with high specificity.

Emerging Opportunity Trends

The most lucrative opportunity within the exosome therapy market extends beyond regenerative treatments and lies in the domain of drug delivery. While regenerative therapies have garnered significant attention for their ability to repair and heal damaged tissues, the potential of exosomes as highly efficient drug delivery vehicles is emerging as a transformative frontier with even greater commercial promise. This opportunity is driven by the limitations of current drug delivery systems in the global biologics market, which predominantly depend on Lipid Nanoparticles (LNPs) and viral vectors. Although these technologies have achieved considerable success, they are often accompanied by significant drawbacks, such as triggering toxicity or provoking immune responses.

Barriers to Optimization

The growth of the exosome therapy market faces significant challenges due to the lack of standardization and quality control across the industry. Currently, there are no universally accepted protocols for the isolation, characterization, and manufacturing of exosomes, which creates considerable variability in how these therapies are produced. This absence of standardized procedures results in high batch-to-batch variability, often exceeding 20%, meaning that the composition and quality of exosome products can differ substantially from one production run to another. Such inconsistencies undermine the reliability and predictability of therapeutic outcomes, which are critical factors for gaining the trust of clinicians, patients, and regulators alike.

Detailed Market Segmentation

By treatment setting, the hospital-based therapies segment emerged as the largest treatment setting within the exosome therapy market, capturing a significant market share of 39%. This leadership position is largely attributed to the nature of the conditions treated and the complexity involved in administering certain exosome therapies. Many of these therapies, particularly those designed for acute and severe conditions such as Acute Respiratory Distress Syndrome (ARDS), require careful and continuous inpatient monitoring to ensure patient safety and optimal therapeutic outcomes.

By therapeutic use case, the regenerative therapies segment holds a commanding position within the exosome therapy market, securing a leading market share of 52% in 2025. This dominance is largely driven by the clinical validation of exosomes' remarkable ability to accelerate tissue repair, especially in the treatment of chronic wounds. Unlike traditional cell-based grafts, which often involve complex procedures and carry risks such as immune rejection or limited integration, exosome therapies offer a more efficient and less invasive alternative.

By exosome source type, the stem cell-derived exosomes segment stood out by securing the largest market share, commanding an impressive 62% in 2025. This dominant position reflects the unique biological advantages that stem cell-derived exosomes offer compared to other sources. Among stem cells, Mesenchymal Stem Cells (MSCs) have emerged as the preferred "bio-factories" within the industry. MSCs are especially valued because their exosomes are naturally enriched with a diverse array of bioactive lipids and proteins that play critical roles in tissue repair and regeneration.

By therapy modality, the autologous exosome therapy category emerged as the clear leader, capturing the largest market share of 57% in 2025. This dominance is firmly grounded in scientific rationale, as autologous therapies utilize exosomes derived directly from the patient's own cells. This approach offers superior biocompatibility, significantly minimizing the risk of immune rejection that can occur with allogeneic therapies, which use exosomes sourced from donors. Because the exosomes are patient-specific, they are more readily accepted by the body's immune system, enhancing both safety and therapeutic efficacy.

Segment Breakdown

By Therapy Modality

  • Autologous Exosome Therapy
  • Patient-derived cell exosomes
  • Point-of-care or near-patient processing
  • Allogeneic Exosome Therapy
  • Donor-derived standardized exosomes
  • Off-the-shelf exosome preparations

By Treatment Setting

  • Hospital-based therapies
  • Specialty clinics
  • Orthopedic clinics
  • Neurology clinics
  • Oncology clinics
  • Ambulatory surgical centers
  • Wellness/aesthetic centers

By Therapeutic Use Case

  • Regenerative therapies
  • Musculoskeletal repair
  • Wound healing
  • Anti-inflammatory therapies
  • Neurorestorative therapies
  • Cardiometabolic therapies
  • Aesthetic & cosmetic therapies
  • Skin rejuvenation
  • Hair restoration
  • Supportive/adjunctive therapies

By Administration Approach

  • Systemic therapy
  • IV-based exosome therapy
  • Local therapy
  • Intra-articular
  • Intradermal
  • Intrathecal
  • Topical application

By Exosome Source Type

  • Stem cell-derived exosomes
  • Immune cell-derived exosomes
  • Tissue-derived exosomes
  • Plant-derived exosomes

By Regulatory Classification

  • Regulated therapeutic procedures
  • Compassionate-use / experimental therapies
  • Non-regulated / wellness-based therapies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Geography Breakdown

  • North America is not only leading the global exosome therapy market but is also setting the standards that other regions are beginning to follow. In 2025, the region commands a substantial 46.80% share of the market, highlighting its pivotal role in shaping the future of exosome therapies worldwide. This dominance is largely attributed to the region's regulatory environment, which embraces a "high-risk, high-reward" approach. This framework encourages innovation by allowing promising therapies to advance rapidly through clinical development while providing clear pathways for regulatory approval.
  • A major milestone that catalyzed North America's leadership was the historic filing on January 2, 2025, of the first Biologics License Application (BLA) by Capricor Therapeutics. This event was a watershed moment because it effectively positioned the U.S. Food and Drug Administration (FDA) as the global gatekeeper for exosome therapy approvals. The FDA's clear regulatory stance provided much-needed clarity and legitimacy to the field, alleviating uncertainties that had previously slowed investment and development. As a result, venture capitalists gained increased confidence in the market's potential, leading to a surge in funding.

Leading Market Participants

  • Aethlon Medical Inc.
  • Bluebird Bio Inc.
  • Capricor Therapeutics Inc.
  • Codiak BioSciences Inc.
  • EV Therapeutics
  • Evox Therapeutics Ltd.
  • Exosome Sciences Inc.
  • Invivo Therapeutics Holdings Corp.
  • Kintor Pharmaceutical Limited
  • MBR Therapeutics
  • Medivir AB
  • NanoString Technologies Inc.
  • ReNeuron Group plc
  • Sorrento Therapeutics Inc.
  • System Biosciences LLC
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Exosome Therapy Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Exosome Therapy Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material & Biological Source Providers
    • 3.1.2. Exosome Isolation & Manufacturing Technology Providers
    • 3.1.3. Contract Development & Manufacturing Organizations (CDMOs)
    • 3.1.4. Therapy Developers & Biotechnology Companies
    • 3.1.5. Healthcare Providers & Clinical Institutions
  • 3.2. Industry Outlook
    • 3.2.1. Clinical Development Landscape
    • 3.2.2. Regulatory Landscape
    • 3.2.3. Disease Burden & Therapeutic Potential
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis

Chapter 4. Global Exosome Therapy Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Exosome Therapy Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Therapy Modality
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Autologous Exosome Therapy
          • 5.2.1.1.1.1. Patient-derived cell exosomes
          • 5.2.1.1.1.2. Point-of-care or near-patient processing
        • 5.2.1.1.2. Allogeneic Exosome Therapy
          • 5.2.1.1.2.1. Donor-derived standardized exosomes
          • 5.2.1.1.2.2. Off-the-shelf exosome preparations
    • 5.2.2. By Treatment Setting
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Hospital-based therapies
        • 5.2.2.1.2. Specialty clinics
          • 5.2.2.1.2.1. Orthopedic clinics
          • 5.2.2.1.2.2. Neurology clinics
          • 5.2.2.1.2.3. Oncology clinics
        • 5.2.2.1.3. Ambulatory surgical centers
        • 5.2.2.1.4. Wellness/aesthetic centers
    • 5.2.3. By Administration Approach
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Systemic Administration
          • 5.2.3.1.1.1. Intravenous (IV)
        • 5.2.3.1.2. Localized Administration
          • 5.2.3.1.2.1. Intra-articular
          • 5.2.3.1.2.2. Intradermal
          • 5.2.3.1.2.3. Intrathecal
          • 5.2.3.1.2.4. Topical application
    • 5.2.4. By Exosome Source Type
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Stem cell-derived exosomes
        • 5.2.4.1.2. Immune cell-derived exosomes
        • 5.2.4.1.3. Tissue-derived exosomes
        • 5.2.4.1.4. Plant-derived exosomes
    • 5.2.5. By Regulatory Classification
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Regulated therapeutic procedures
        • 5.2.5.1.2. Compassionate-use / experimental therapies
        • 5.2.5.1.3. Non-regulated / wellness-based therapies
    • 5.2.6. By Therapeutic Use Case
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. Regenerative therapies
          • 5.2.6.1.1.1. Musculoskeletal repair
          • 5.2.6.1.1.2. Wound healing
        • 5.2.6.1.2. Anti-inflammatory therapies
        • 5.2.6.1.3. Neurorestorative therapies
        • 5.2.6.1.4. Cardiometabolic therapies
        • 5.2.6.1.5. Aesthetic & cosmetic therapies
          • 5.2.6.1.5.1. Skin rejuvenation
          • 5.2.6.1.5.2. Hair restoration
        • 5.2.6.1.6. Supportive/adjunctive therapies
    • 5.2.7. By Region
      • 5.2.7.1. Key Insights
        • 5.2.7.1.1. North America
          • 5.2.7.1.1.1. The U.S.
          • 5.2.7.1.1.2. Canada
          • 5.2.7.1.1.3. Mexico
        • 5.2.7.1.2. Europe
          • 5.2.7.1.2.1. Western Europe
            • 5.2.7.1.2.1.1. The UK
            • 5.2.7.1.2.1.2. Germany
            • 5.2.7.1.2.1.3. France
            • 5.2.7.1.2.1.4. Italy
            • 5.2.7.1.2.1.5. Spain
            • 5.2.7.1.2.1.6. Rest of Western Europe
          • 5.2.7.1.2.2. Eastern Europe
            • 5.2.7.1.2.2.1. Poland
            • 5.2.7.1.2.2.2. Russia
            • 5.2.7.1.2.2.3. Rest of Eastern Europe
        • 5.2.7.1.3. Asia Pacific
          • 5.2.7.1.3.1. China
          • 5.2.7.1.3.2. India
          • 5.2.7.1.3.3. Japan
          • 5.2.7.1.3.4. South Korea
          • 5.2.7.1.3.5. Australia & New Zealand
          • 5.2.7.1.3.6. ASEAN
            • 5.2.7.1.3.6.1. Indonesia
            • 5.2.7.1.3.6.2. Malaysia
            • 5.2.7.1.3.6.3. Thailand
            • 5.2.7.1.3.6.4. Singapore
            • 5.2.7.1.3.6.5. Rest of ASEAN
          • 5.2.7.1.3.7. Rest of Asia Pacific
        • 5.2.7.1.4. Middle East & Africa
          • 5.2.7.1.4.1. UAE
          • 5.2.7.1.4.2. Saudi Arabia
          • 5.2.7.1.4.3. South Africa
          • 5.2.7.1.4.4. Rest of MEA
        • 5.2.7.1.5. South America
          • 5.2.7.1.5.1. Argentina
          • 5.2.7.1.5.2. Brazil
          • 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Therapy Modality
      • 6.2.1.2. By Treatment Setting
      • 6.2.1.3. By Administration Approach
      • 6.2.1.4. By Exosome Source Type
      • 6.2.1.5. By Regulatory Classification
      • 6.2.1.6. By Therapeutic Use Case
      • 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Therapy Modality
      • 7.2.1.2. By Treatment Setting
      • 7.2.1.3. By Administration Approach
      • 7.2.1.4. By Exosome Source Type
      • 7.2.1.5. By Regulatory Classification
      • 7.2.1.6. By Therapeutic Use Case
      • 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Therapy Modality
      • 8.2.1.2. By Treatment Setting
      • 8.2.1.3. By Administration Approach
      • 8.2.1.4. By Exosome Source Type
      • 8.2.1.5. By Regulatory Classification
      • 8.2.1.6. By Therapeutic Use Case
      • 8.2.1.7. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Therapy Modality
      • 9.2.1.2. By Treatment Setting
      • 9.2.1.3. By Administration Approach
      • 9.2.1.4. By Exosome Source Type
      • 9.2.1.5. By Regulatory Classification
      • 9.2.1.6. By Therapeutic Use Case
      • 9.2.1.7. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Therapy Modality
      • 10.2.1.2. By Treatment Setting
      • 10.2.1.3. By Administration Approach
      • 10.2.1.4. By Exosome Source Type
      • 10.2.1.5. By Regulatory Classification
      • 10.2.1.6. By Therapeutic Use Case
      • 10.2.1.7. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Aethlon Medical Inc.
  • 11.2. Capricor Therapeutics Inc.
  • 11.3. Codiak BioSciences
  • 11.4. EV Therapeutics
  • 11.5. Evox Therapeutics Ltd.
  • 11.6. Exosome Sciences Inc.
  • 11.7. ReNeuron Group plc
  • 11.8. System Biosciences LLC
  • 11.9. Aruna Bio, Inc.
  • 11.10. NurExone Biologic
  • 11.11. Aegle Therapeutics
  • 11.12. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators